A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of once-a-day orally or IV dose of Letermovir (MK-8228) in Chinese adult Hematopoietic Stem Cell Transplant (HSCT) recipients for the prevention of clinically significant Cytomegalovirus (CMV) Infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Letermovir Chinese HSCT recipients will receive 240 mg [for participants on Cyclosporin A (CsA)] or 480 mg (for participants not on CsA) Letermovir orally or IV once daily through week 14 (~100 days) post-transplant. |
Drug: Letermovir
Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With Clinically significant CMV Infection up to Week 24 Post-transplant (~ 6 months) [Up to Week 24 post-transplant (~ 6 months).]
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection will be assessed.
Secondary Outcome Measures
- Number of Participants Experiencing Adverse Events [Up to ~ 24 weeks (~ 6 months) post-transplant]
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention
- Number of Participants Discontinued From Study Medication Due to an Adverse Event [Up to 14 weeks post-transplant]
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be assessed.
- Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant [Up to Week 14 post-transplant.]
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection will be assessed.
- Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant [Up to Week 14 post-transplant]
Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy will be assessed.
- Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant [Up to Week 24 post-transplant]
Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy will be assessed.
- Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant [Up to Week 14 post-transplant]
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease will be assessed.
- Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant [Up to Week 24 post-transplant]
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease will be assessed.
- Percentage of Participants With All-cause Mortality up to Week 14 Post-transplant [Up to Week 14 post-transplant]
The percentage of participants who died due to any cause up to week 14 post-transplant will be determined.
- Percentage of Participants With All-cause Mortality up to Week 24 Post-transplant [Up to Week 24 post-transplant]
The percentage of participants who died due to any cause up to week 24 post-transplant will be determined.
Eligibility Criteria
Criteria
The key inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
-
Male/Female Chinese adult participant of an allogeneic Hematopoietic Stem Cell Transplant (HSCT).
-
Has documented positive Cytomegalovirus (CMV) serostatus (CMV immunoglobulin G [IgG] seropositive) for recipient (R+) at the time of screening.
-
Is receiving a first allogeneic HSCT.
-
Is within 28 days post-HSCT at the time of randomization.
-
Female participant is not a Woman of Child Bearing Potential (WOCBP) or is a WOBCP who agrees to use acceptable contraception during the treatment period and for ≥28 days after the last dose of study drug.
Exclusion Criteria:
-
Received a previous allogeneic HSCT.
-
Has a history of CMV end-organ disease within 6 months prior to randomization.
-
Has evidence of CMV viremia at any time from HSCT procedure until the time of randomization.
-
Has severe hepatic insufficiency.
-
Is a) on renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) OR b) has end stage renal impairment with a creatinine clearance <=10 mL/min within 5 days prior to randomization.
-
Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency.
-
Has an uncontrolled infection on the day of randomization.
-
Has rapidly progressing disease that requires mechanical ventilation or is hemodynamically unstable.
-
Has a documented positive result for a human immunodeficiency virus antibody (HIV-Ab) test at any time prior to randomization, or for hepatitis C virus antibody (HCV-Ab) with detectable HCV ribonucleic acid (RNA), or hepatitis B surface antigen (HBsAg) within 90 days prior to randomization.
-
Has active solid tumor malignancies except localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas).
-
Has received any prohibited medications within 2 days prior to initiation of treatment with Letermovir.
-
Is anticipated to be treated with Traditional Chinese Medicine or herbal medicine during the study treatment period and for 14 days after study medication.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Merck Sharp & Dohme LLC
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 8228-045
- MK-8228-045